To investigate the possibility of diering roles for cyclins D1 and D2 in breast epithelial cells, we examined the expression, cell cycle regulation and activity of these two G 1 cyclins in both 184 normal breast epithelial cells and T-47D breast cancer cells. Synchronisation studies in 184 cells demonstrated that cyclin D1 and cyclin D2 were dierentially regulated during G 1 , with cyclin D2 abundance increasing by 3.7-fold but only small changes in cyclin D1 abundance observed. The functional consequences of increased cyclin D2 expression were examined in T-47D cells, which express no detectable cyclin D2. Induced expression of cyclin D2 resulted in increases in cyclin E expression, pRB phosphorylation and the percentage of cells in S-phase, while constitutive expression resulted in a consistent trend toward reduced dependence on serum for continued proliferation. Thus, cyclin D2 is a positive regulator of G 1 progression in breast cells analogous to the well-documented eects of cyclin D1. Indeed, equimolar concentrations of inducible cyclin D1 and D2 resulted in quantitatively similar cell cycle eects. Marked divergence was found, however, in the CDKs activated by the two cyclins in breast epithelial cells. Cyclin D2 complexes contained a higher Cdk2/Cdk4 ratio than cyclin D1 complexes. The cyclin D2-associated kinase activity was largely inhibited by Cdk2-speci®c inhibitors and could phosphorylate histone H1, a substrate for Cdk2 but not for Cdk4 and Cdk6. Therefore, cyclin D2 preferentially activated Cdk2 in breast epithelial cells. In contrast, Cdk4 and Cdk6 were predominantly responsible for cyclin D1-associated kinase activity as previously reported. Thus, although cyclins D1 and D2 elicited similar eects on breast epithelial cell cycle progression they appeared to achieve this end via activation of dierent CDKs. This is the ®rst evidence of cyclin D2 activating Cdk2 in mammalian cells thus providing further evidence that D-type cyclins are not necessarily redundant.
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Introduction
Cyclins D1 and D2 are closely related proteins that control cell cycle progression during G 1 phase. Induced expression of ectopic cyclin D1 in rodent ®broblasts or human epithelial cells accelerates transit through G 1 phase, decreases cell size and reduces dependence on serum (Jiang et al., 1993; Quelle et al., 1993; Musgrove et al., 1994; Resnitzky et al., 1994; Zwijsen et al., 1996) .
Similarly, overexpression of cyclin D2 in myeloid cells results in a decrease in the duration of G 1 and an increase in the percentage of cells in S-phase Kato and Sherr, 1993) . Microinjection or electroporation of cyclin D1 or cyclin D2 antibodies demonstrated that these proteins were not only ratelimiting but essential for progress through G 1 (Baldin et al., 1993; Quelle et al., 1993; Lukas et al., 1995b) . These eects are thought to be mediated by activation of cyclin-dependent kinases (CDKs) and consequent phosphorylation of the product of the retinoblastoma susceptibility gene, pRB (Hunter and Pines, 1994; Sherr, 1994) . Phosphorylation of pRB by cyclin/CDK complexes in late G 1 phase relieves its inhibitory role by releasing transcription factors, such as E2F, essential for progression through S-phase (Sherr, 1994; Weinberg, 1995) . Cyclin D-associated CDKs are pRB kinases in vitro (Matsushime et al., 1994; Meyerson and Harlow, 1994) and, together with cyclin E/Cdk2, are also important pRB kinases in vivo (Sherr, 1994; Weinberg, 1995) . There is clear evidence that both cyclin D1 and D2 have a codependent relationship with pRB: cells that lack functional pRB have reduced expression of these D type cyclins (Bates et al., 1994b; Lukas et al., 1995a) and ectopic expression of either protein can rescue cells from the growthsuppressive eect of pRB (Dowdy et al., 1993; Ewen et al., 1993) . These similar roles in G 1 progression and interaction with pRB, together with the observed sequence homology suggest that cyclins D1 and D2 have similar functional properties.
In spite of these similarities in function, human cyclin D1 and D2 are more closely related to the corresponding murine cyclins than to each other (490% amino acid identity, compared with 63%). Across a range of human diploid cells and tumor cell lines of breast, colon, lymphoid and sarcoma origin, cyclin D2 expression was restricted compared to cyclin D1 (Buckley et al., 1993; Palmero et al., 1993; Lukas et al., 1995b) . Cyclin D1 was expressed in most of the cell types examined with the exception of T lymphocytes, which only expressed cyclin D2. Osteosarcomas and normal breast epithelial cells expressed both cyclins D1 and D2 (Buckley et al., 1993; Lukas et al., 1995b) . Where both cyclins are expressed they appear to act cooperatively in controlling G 1 progression (Bartkova et al., 1995) . This raises the possibility that their functions are not wholly redundant.
Some studies have pointed to functional dierences between cyclins D1 and D2 e.g. overexpression of cyclin D2, but not cyclin D1, in 32D myeloid cells disables the dierentiation pathway . A basis for functional dierences is suggested by dierences in the ability of cyclins D1 and D2 to interact with other cellular proteins including CDKs.
Although cyclins D1 and D2 bind Cdk2, Cdk4 and Cdk6 in mammalian cells (Matsushime et al., 1992; Xiong et al., 1992b; Bates et al., 1994a; Meyerson and Harlow, 1994; Lukas et al., 1995b) , the cyclin D1-Cdk2 complex appears to be inactive (Dulic et al., 1993; Higashi et al., 1996) . While cyclin D1 or cyclin D2 immunoprecipitates phosphorylate pRB in vitro, a number of laboratories have been unable to demonstrate cyclin D1-associated kinase activity using histone H1, the preferred in vitro substrate for Cdk2 (Matsushime et al., 1991 (Matsushime et al., , 1994 Ewen et al., 1993; Quelle et al., 1993) . Consistent with these observations, cyclin D1 activates Cdk4 and Cdk6, but not Cdk2, when coexpressed in insect cells whereas cyclin D2 activates all three kinases in this system (Matsushime et al., 1992 (Matsushime et al., , 1994 Ewen et al., 1993; Meyerson and Harlow, 1994) .
Although both cyclin D1 and D2 are putative oncogenes and are expressed in at least some breast epithelial cells, only cyclin D1 overexpression has been implicated in the development and progression of breast cancer. Cyclin D1 is ubiquitously expressed in epithelial cell lines derived from both normal breast and breast cancer (Buckley et al., 1993; Lukas et al., 1994 Lukas et al., , 1995b Tam et al., 1994b) and is frequently overexpressed in breast cancer (Buckley et al., 1993; Bartkova et al., 1994; Gillett et al., 1994; Hui et al., 1996) . In contrast, cyclin D2 is expressed at very low levels or is absent in most breast cancer cell lines (Buckley et al., 1993; Tam et al., 1994b; Lukas et al., 1995b) . Cyclin D2 mRNA and protein are abundant in some normal breast epithelial cells but very little cyclin D2 protein was detected in cultured breast luminal epithelial cells, the cell type from which most breast cancers evolve (Lukas et al., 1995b) .
Cyclin D1 is an important cell cycle regulatory gene in human breast epithelial cells where it is both necessary and sucient for G 1 progression and is intimately involved in the mitogenic response to growth factors and steroids (Sweeney et al., 1996) . Furthermore, cyclin D1 is necessary for normal mammary development (Fantl et al., 1995; Sicinski et al., 1995) . In contrast, the role of cyclin D2 in these cells remains to be established since there are relatively few published data addressing the functional significance of cyclin D2 and these studies are mostly con®ned to rodent ®broblasts and haematopoietic cells Ando et al., 1993; Kato and Sherr, 1993; Quelle et al., 1993; Lukas et al., 1995b) . Consequently, to address the potential signi®cance of the dierential expression of cyclins D1 and D2 in normal and neoplastic breast epithelial cells we compared the regulation and function of these cyclins in normal breast epithelial cells expressing both cyclins and in T-47D human breast cancer cells expressing ectopic cyclin D2.
Results
Cyclin D2 and cyclin D1 are dierentially regulated following growth factor stimulation of normal breast epithelial cells
To determine whether cyclins D1 and D2 were coordinately regulated during cell cycle progression, the 184 normal breast epithelial cell line was arrested in growth factor depleted medium and then stimulated to re-initiate cell cycle progression by the addition of a growth supplement containing bovine pituitary extract. Analysis of cell cycle phase distribution by¯ow cytometry indicated that growth factor-depleted cells had a markedly reduced percentage of cells in S-phase (9%) compared with exponentially growing cells (*22%) (Figure 1a ). The percentage of cells in Sphase increased markedly between 6 and 12 h after growth factor addition, reaching a maximum of 34% at 16 h. The increase in the percentage of cells in Sphase was followed by an increase in the G 2 +M fraction, between 12 and 16 h. Thus the mitogenstimulated cells progressed synchronously through the cell cycle and this was accompanied by the sequential induction of G 1 cyclins (Figure 1a and b) . Expression of cyclin D2 protein began to increase in early G 1 phase and continued to increase, reaching a maximum at 16 h (3.7-fold), when cells were in mid-S-phase, after which the protein expression declined. Cyclins D1 and E showed little change during the timecourse, with at most a 30% increase in cyclin D1 by late G 1 ( Figure  1c) . Similarly, there was little change in the expression of Cdk4 or Cdk6. In contrast, there was a fourfold increase in Cdk2 protein beginning as early as 6 h after mitogen treatment which was maintained for the 24 h of the experiment (Figure 1b) . Thus, while some of the changes were modest, the degree of synchrony was sucient to detect changes in the expression of cyclin D2 and indicate clear dierences in the pattern of induction of cyclins D1 and D2 during progress through the cell cycle in these breast epithelial cells.
Since pRB is a physiological target for the activities of these cyclins and CDKs, changes in pRB expression and phosphorylation were also examined. In growth factor-depleted cells low levels of pRB were detected, predominantly in the faster migrating, underphosphorylated form (Figure 1b) . The total abundance of pRB increased markedly as cells progressed into Sphase at 9 ± 12 h. In addition, the proportion of pRB in the more slowly migrating, phosphorylated form (ppRB) increased and by 9 h this was the predominant form. These data are compatible with growth factor stimulated cell cycle progression being mediated by increased expression of G 1 cyclins, leading to activation of CDKs and pRB phosphorylation as has been previously described in several cell systems. However, perhaps unexpectedly they reveal a potential major role for cyclin D2 in cells that also express cyclin D1.
Cyclin D2 associates with Cdk2, Cdk4 and Cdk6 and the cyclin D2/Cdk2 complex is active in 184 cells
To identify whether cyclins D1 and D2 display biochemical dierences re¯ecting their dierential regulation in breast epithelial cells, CDK association and activity were examined in exponentially proliferating 184 cells. Both cyclin D1 and cyclin D2 immunoprecipitates from 184 cells contained Cdk2, Cdk4 and Cdk6 within the complexes as detected by Western blot analysis but there were marked differences in the relative abundance of dierent CDKs in the cyclin D1 and D2 complexes (Figure 2a ). Whole cell lysate blotted in parallel indicated that the percentage of the total Cdk2 pool immunoprecipitated with cyclin D2 was greater than the percentage of the Cdk4 or Cdk6 pools bound to cyclin D2. Indeed Cdk4 was only apparent in cyclin D2 complexes upon extended exposure of the autoradiograms in contrast with the readily apparent Cdk4 protein in cyclin D1 complexes. To test if this dierence in complex composition was re¯ected in substrate speci®city, the dierential activity of cyclin D1 and D2 complexes was Cyclin D2 or cyclin D1 immunocomplexes from exponentially growing 184 cells were used in an in vitro kinase assay using recombinant GST-pRB protein or histone H1 protein as substrate. These kinase reactions were performed in the absence or presence of 5 mg GST-p21 or GST-p16 fusion proteins or 50 mM of the Cdk2-speci®c chemical inhibitors roscovitine (ros) or olomoucine (olo). (c) The results of three independent cyclin D1 and cyclin D2 kinase assays, using GST-pRB substrate, are shown as percentage inhibition relative to activity without inhibitor addition examined using antibodies speci®c for the individual cyclins (Lukas et al., 1995b; Musgrove et al., 1996) . Kinase activity was readily detected in both cyclin D2 and cyclin D1 immunoprecipitates from 184 cells using a bacterially expressed truncated GST-pRB fusion protein as substrate ( Figure 2b ). Preincubation of the immune complexes with recombinant GST-p16, a speci®c Cdk4/Cdk6 inhibitor (Serrano et al., 1993) , signi®cantly decreased the pRB kinase activity of the cyclin D1 complexes but had little or no eect on the activity of the cyclin D2 complexes (Figure 2b and c).
In contrast, Cdk2-speci®c chemical inhibitors, olomoucine and roscovitine (Glab et al., 1994; Vesely et al., 1994; Schulze-Gahmen et al., 1995) , decreased cyclin D2-associated kinase activity but had little eect on cyclin D1-associated kinase assays performed in parallel (Figure 2b and c). As expected, the general CDK-inhibitor p21 (WAF1, CIP1, Harper et al., 1993; Xiong et al., 1993) signi®cantly inhibited both cyclin D1-and D2-associated kinase activity (Figure 2b and c). Thus the cyclin D1-associated kinase activity in 184 cells was apparently due to Cdk4 and/or Cdk6 while in contrast much of the cyclin D2-associated kinase activity appeared to be due to Cdk2. To con®rm this conclusion cyclin D2-associated kinase assays were performed using histone H1 as substrate, since this is a preferred substrate for Cdk2 but is not phosphorylated by Cdk4 or Cdk6. These assays demonstrated that cyclin D2 immunoprecipitates contained histone H1 kinase activity that was inhibited by GST-p21, olomoucine and roscovitine ( Figure 2b ). As has been reported by others (Dulic et al., 1993; Higashi et al., 1996) cyclin D1 complexes, which contained Cdk2 in breast epithelial cells, did not phosphorylate histone H1 (data not shown).
Induction of cyclin D2 in T-47D breast cancer cells is followed by increases in cyclin E protein expression, pRB phosphorylation and percentage of cells in S-phase
Since the data presented above indicated that cyclins D1 and D2 activated dierent CDKs and therefore might have diering functions in breast epithelial cells, the eects of ectopic cyclin D2 expression were examined in T-47D human breast cancer cells. This cell line was chosen because, unlike the 184 cell strain, it has no detectable cyclin D2 protein. Furthermore, T-47D cells do not exhibit ampli®cation or overexpression of other G 1 cyclins (Buckley et al., 1993) . Following growth factor treatment these cells display sequential induction of cyclin mRNA accompanying cell cycle progression, consistent with data from other cell types, indicating that these cells retain at least some of the features of cell cycle control present in normal cells . Furthermore, the eects of ectopic cyclin D1 expression in T-47D cells have been well-characterised: cyclin D1 induction is followed by induction of cyclin E, pRB phosphorylation, and acceleration through G 1 phase (Musgrove et al., 1994 . Hence it was possible to directly compare the eects of the two D-type cyclins in the same cell line. T-47D cells were cotransfected with a vector containing the coding region of cyclin D2 under the control of a zinc-inducible promoter (pDMTcyclin D2) and pSV2neo, and G418-resistant pools of cells selected to generate T-47D DMTcyclin D2 cells. Similarly selected cells transfected with the vector only, i.e. T-47D DMT cells, were employed as controls. Since preliminary experiments indicated that serum-free medium allowed maximum stimulation of the transfected gene in this system (data not shown), cells were transferred to serum-free medium containing insulin at the time of zinc addition. Under these conditions T-47D cells still proliferate exponentially, albeit sub-maximally. Signifi- cant amounts of cyclin D2 protein were detectable as early as 3 h following zinc treatment and maximal protein expression occurred at *12 h (Figure 3a and b). To identify the molecular events occurring subsequent to the induction of cyclin D2 we examined the expression of other cyclins and CDKs over the same time-course. Cdk4 and Cdk2 protein levels remained constant for the duration of the experiment while Cdk6 displayed approximately a twofold increase at 12 to 16 h after zinc treatment (Figure 3a and data not shown). Cyclin D1 protein levels did not change during G 1 but declined after 18 h of zinc treatment when a signi®cant proportion of the cells were in Sphase. Cyclin E protein levels began to increase above control levels *3 h after the appearance of cyclin D2 protein and reached maximum levels at *12 h after zinc treatment (Figure 3a and c). This increase in cyclin E expression was associated with cyclin D2 induction rather than zinc treatment since there was little eect of zinc treatment on cyclin E expression in T-47D DMT cells ( Figure 3c , right panel). Phosphorylation of pRB has been observed following cyclin D1 induction in T-47D cells . Therefore, pRB phosphorylation in vivo was examined following cyclin D2 induction. Zinc induction of cyclin D2 led to increased pRB abundance and increased phosphorylation ( Figure 4a ). The ratio of phosphorylated to underphosphorylated pRB (i.e. ppRB/pRB) relative to that in vehicle-treated control cells increased after 6 h, reaching a maximum at 18 h ( Figure 4B ). Little change in pRB phosphorylation occurred within 18 h of zinc treatment of T-47D DMT cells. Thus, the increase in pRB phosphorylation occurred approximately 3 ± 6 h after cyclin D2 induction which is compatible with activation of endogenous CDKs by ectopic cyclin D2. To con®rm that cyclin D2 induction increased cyclin D2-associated kinase activity, the kinase activity of cyclin D2 immunoprecipitates was measured using GST-pRB substrate. In untreated T-47D DMTcyclin D2 cells only background phosphorylation was detected, similar to that obtained in parallel immunoprecipitates using an irrelevant control antibody (a mouse monoclonal IgG2b isotypic control antibody). However, following 9 or 12 h zinc treatment, when substantial amounts of cyclin D2 protein were present, kinase activity was increased by up to threefold above background phosphorylation at 0 h (Figure 4c ). Apparent in this ®gure is an unidenti®ed, phosphorylated band that migrated just above the GST-pRB in vitro substrate. This was a consistent ®nding in zinc-treated cells and may represent an endogenous substrate that coimmunoprecipitates with the cyclin D2 complex.
CDK activation and pRB phosphorylation were followed by an increase in the number of cells entering S-phase and corresponding decrease in the proportion of cells in G 1 phase upon induced expression of cyclin D2 in T-47D cells. This was ®rst apparent at 12 h and was maximal at *18 h, when G 1 had decreased from 79% to 46% and S-phase had increased from 17% to 45% (Figure 4d ). Identical experiments in control cells transfected with the empty vector demonstrated that zinc alone was capable of inducing a modest degree of cell cycle progression. The cyclin D2-expressing cells, however, consistently showed a greater number of cells progressing into S-phase in parallel experiments con®rming that the cell cycle changes were not solely due to zinc treatment ( Figure 4d and data not shown). Thus, these studies indicated many similarities between the eects of cyclin D1 and cyclin D2 induction in T-47D cells: induction of either cyclin was followed by induction of cyclin E, pRB phosphorylation and cell cycle progression.
Ectopic expression of cyclin D2 does not render T-47D cells completely mitogen independent
In view of data which indicated that increased expression of D-type cyclins in breast cancer cells resulted in reduced serum dependence (Musgrove et al., 1994; Zwijsen et al., 1996) , the eect of cyclin D2 expression on the response to serum deprivation was examined using T-47D cells transfected with cyclin D2 under the control of the constitutive CMV promoter. Four independent pools of cyclin D2-transfected cells and three control pools transfected with vector alone were generated. Western blotting of lysates ( Figure 5A ) con®rmed that cyclin D2 was expressed in the T-47D CMVcyclin D2 lines but not in the T-47D CMV control lines. The growth rates of representative cell lines were then determined and doubling times calculated during exponential growth in dierent serum concentrations (Figure 5b ). In each of four independent experiments, the doubling time of vectortransfected cells maintained in medium supplemented with 5% FCS was 1 ± 1.5 days, similar to the doubling time of stock cultures of the parental T-47D cells. The doubling time increased at lower serum concentrations to reach 2.5 ± 3.5 days in the absence of serum, again consistent with data obtained using the parental cell line (Reddel et al., 1985) . In four independent experiments there was a consistent trend towards lower doubling times in cyclin D2-transfected cells compared with vector-transfected control cells over a range of serum concentrations. In some experiments, such as that shown in Figure 5b , the doubling time of the cyclin D2-expressing cells in serum-free medium was lower than that of control cells but such clear distinction between doubling times was not consistently seen and the dierences did not always reach statistical signi®cance. In parallel experiments the cell cycle phase distribution of cyclin D2-transfected cells was also examined in a range of serum concentrations. In serum-containing medium there was no dierence in the cell cycle phase distribution between cyclin D2 transfectants and controls (Figure 5c ). In serum free medium, however, there was a statistically signi®cant (P=0.041) increase in the percentage of cells in S-phase in the cyclin D2-expressing cells compared to the control cells (Figure 5c ). Together these data suggest that constitutive expression of cyclin D2 has a similar eect to constitutive expression of cyclin D1 in breast cancer cells (Zwijsen et al., 1996) , i.e. to decrease the dependence on serum for proliferation. In the experiment shown it appeared that the doubling time of cyclin D2-expressing cells in 0% FCS diered little from the doubling time in 5% FCS (Figure 5b ) but again this was not a consistent ®nding. In most experiments the doubling time was clearly increased with reduction of serum concentration in the cells expressing cyclin D2 and hence constitutive expression of cyclin D2 was not sucient to render the cells completely mitogen-independent.
Cyclin D2 associates with Cdk2, Cdk4 and Cdk6 when ectopically expressed in T-47D cells and both cyclin D2/ Cdk2 and cyclin D2/Cdk4/Cdk6 complexes are active
The data in Figure 2 raised the possibility that the eects of cyclin D1 and D2 in breast cancer cells might be mediated by dierent CDKs. To address this possibility exogenous cyclin D2 was immunoprecipitated from T-47D cyclin D2 transfectants and the associated CDKs identi®ed by Western blotting. Cdk2, Cdk4 and Cdk6 were all associated with cyclin D2 (Figure 6a) . Consistent with the data from 184 cells presented in Figure 2 , there was a greater percentage of the Cdk2 pool associated with cyclin D2 than either Cdk4 or Cdk6. Cyclin D2-associated kinase activity was observed using both histone H1 and GST-pRB substrates following ectopic expression of cyclin D2 in T-47D cells and this activity was inhibited by preincubation with GST-p21 (Figure 6b and c) and data not shown). When the same antibody was used to immunoprecipitate proteins from lysates of T-47D cells transfected with vector alone, only low, background, levels of histone H1 kinase activity were observed (Figure 6b ). While the GST-pRB kinase activity from the cyclin D2-expressing cells was inhibited by preincubation with GST-p21 addition of GST-p16 was less eective (data not shown). Together these data indicate that, like the endogenous cyclin D2 in 184 cells, ectopically expressed cyclin D2 activated Cdk2 to a greater extent than Cdk4 or Cdk6.
Induction of cyclin D2 or cyclin D1 has quantitatively similar eects on T-47D cell cycle progression
The eects of induction of cyclin D2 on cell cycle progression, cyclin E expression and pRB phosphorylation in T-47D cells were qualitatively similar to those previously described for cyclin D1 (Musgrove et al., 1994) . However, the eects of cyclin D1 on the percentage of cells moving into S-phase appeared quantitatively greater than those of cyclin D2. Treatment of T-47D DMTcycD1-3 cells with 50 mM zinc resulted in an approximate fourfold increase in the percentage of cells in S-phase (Musgrove et al., 1994) whilst analogous experiments in cyclin D2 transfectants yielded a less than twofold change when background due to the eects of zinc alone was subtracted ( Figure  4d ). This could result from a genuine dierence in the function of cyclins D1 and D2, perhaps resulting from the activation of dierent kinases by these cyclins or merely from a dierence in the level of protein expression following activation of the inducible promoter. To address this question, the concentrations of cyclin D1 and cyclin D2 proteins in cell lysates were determined from standard curves generated with recombinant cyclin D1-GST and cyclin D2-GST fusion proteins expressed in insect cells ( Figure 7A ). These estimates indicated that the maximum levels of cyclin D2 achieved following zinc induction of T-47D DMTcyclin D2 cells were similar to the level of cyclin D2 expression in 184 cells ( Figure 7B ). The cyclin D1 concentration following treatment of T-47D DMTcycD1-3 cells with 50 mM zinc was approximately four times greater than the concentration of cyclin D2 produced following a similar treatment of T-47D DMTcyclin D2 cells. Previous experiments using a range of zinc concentrations demonstrated a linear relationship between induced cyclin D1 abundance and subsequent cell cycle progression ( Figure 7C ). These data were employed to assess the expected eect on the percentage of cells in S-phase of the increment in D cyclin levels in T-47D DMTcyclin D2 cells treated with zinc. An increment of *0.05 ng/ml lysate, i.e. to a total of *0.07 ng/ml lysate, would lead to an increase in the percentage of cells in S-phase of between 11 ± 16% (taken from the 95% con®dence intervals for the line of best ®t). This is comparable with the speci®c increase in the percentage of cells in S-phase due to induction of cyclin D2 of 11% at 18 h (Figure 4d) . Thus, these data suggest that cyclin D2 led to an eect on progression into S-phase quantitatively comparable with the eect of a similar concentration of cyclin D1.
Discussion
Our ®ndings indicate divergence of the regulation and molecular association of cyclins D1 and D2 in breast epithelial cells which is not accompanied by major divergence of their downstream molecular and cell cycle eects. In synchronised 184 breast epithelial cells cyclin D2 protein expression reached a maximum 3.5-fold increase at the G 1 /S-phase boundary compared to G 0 arrested cells. Maximum levels of cyclin D2 protein have also been observed in late G 1 in elutriated lymphocytes, with a similar increase of three-to ®vefold compared to cells at the start of G 1 (Lukas et al., 1995b) . Increases in cyclin D2 mRNA and protein expression were apparent by 2 h after IL-2 stimulation of arrested 32Dc13 murine myeloid cells but in contrast the level of cyclin D2 protein changed very little during the cell cycle in murine erythroleukemia cells Kiyokawa et al., 1994) . These dierences do not appear to depend on the combination of D-type cyclins expressed since lymphocytes, myeloid cells and murine erythroleukemia cells do not express cyclin D1 whilst 184 cells express both cyclins D1 and D2. In normal breast epithelial cells cyclin D2 protein levels were clearly mitogen-regulated while little change in cyclin D1 levels was detected. Dierential regulation of the two cyclins in response to mitogenic signals has been observed previously in ®broblasts where cyclin D1 but not cyclin D2 mRNA is increased in response to stimulation with both serum and PDGF (Winston and Pledger, 1993) . Furthermore, the expression of D type cyclins is also dierentially regulated following induction of apoptosis or differentiation in some cell types (Freeman et al., 1994; Kranenburg et al., 1995) . Hence, some growth stimulatory and inhibitory signals preferentially regulate one of these two D-type cyclins. This may explain why some cells apparently require both cyclin D1 and cyclin D2 whilst other cells predominantly express only one. Both endogenous cyclin D2 in 184 cells and exogenous cyclin D2 in T-47D transfectants bound Cdk2, Cdk4 and Cdk6 (Figures 2 and 6 ). There was apparently less Cdk4 bound to cyclin D2 than to cyclin D1. This is consistent with a previous observation in which cyclin D2 and D1 proteins were immunoprecipitated from Rat-2 and NIH3T3 cells that had been transfected with the respective cyclin gene (Quelle et al., 1993) . Since the cyclin D2 concentration in 184 cells was more than twice that of cyclin D1, the dierence in the amount of coimmunoprecipitated Cdk4 appears unlikely to re¯ect dierences in cyclin abundance but could be due to a dierence in the ability of these cyclins to stably interact with Cdk4 in these cells. In contrast to the ®ndings of Quelle et al. (1993) in Rat-2 and NIH3T3 cells, where Cdk2 was not detected in cyclin D2 immunoprecipitates, we found cyclin D2 bound signi®cant amounts of Cdk2 in breast epithelial cells. Another study using immunoprecipitation followed by Western blotting has shown cyclin D2 bound to all three CDKs in U-2-OS osteosarcoma cells (Lukas et al., 1995b) . Whilst this discrepancy may in part re¯ect dierences in methodology, Cdk2 association with cyclin D1 appears to also be a cell typespeci®c phenomenon (Bates et al., 1994a; Tam et al., 1994a) . Thus cyclin D-CDK association appears not to depend solely on the abundance of the cyclin and CDK even in exponentially proliferating cells, where the postulated assembly factors for these complexes might be expected to be present (Matsushime et al., 1994) .
Results from this study indicate that a major part of the cyclin D2-associated kinase activity in breast epithelial cells expressing either endogenous or exogenous cyclin D2 is due to Cdk2 (Figures 2 and  6 ). Several lines of evidence support this conclusion: the Cdk4/Cdk6-speci®c physical inhibitor p16 (Serrano et al., 1993) had little or no eect on the cyclin D2-associated kinase activity while the Cdk2-speci®c chemical inhibitors, roscovitine and olomoucine (Glab et al., 1994; Vesely et al., 1994; Schulze-Gahmen et al., 1995) did block the kinase activity. Finally, cyclin D2 immunocomplexes phosphorylated histone H1 (Figures  2b and 5b) , a substrate that is not phosphorylated by Cdk4 or Cdk6 (Matsushime et al., 1994; Meyerson and Harlow, 1994) . In contrast, histone H1 kinase activity was not observed in cyclin D2 immunocomplexes from (Musgrove et al., 1994) T cells or 32Dcl3 cells Ando and Grin, 1995) . Although neither study directly examined the constituents of the cyclin D2 complexes, the major catalytic partner was thought to be Cdk4 in these cell types. This conclusion is supported by evidence that constitutive overexpression of Cdk4 in 32Dcl3 cells prevents a TGFb-mediated decrease in cyclin D2-associated kinase activity (Ando and Grin, 1995) , although an alternative explanation of these observations is that the overexpressed Cdk4 may act as a sink for TGFb-induced CDK inhibitors, thus allowing cyclin D2/Cdk2 complexes to be active. When 32D mouse myeloid cells were induced to dierentiate, however, a somewhat greater percentage of total cyclin D2 bound to Cdk2. The authors concluded that the proposed dierentiation-inhibiting eects of cyclin D2 could be mediated through Cdk2, although this was not formally demonstrated . These results contrast with the consistent ®nding that cyclin D1 cannot activate Cdk2 (see Introduction). Thus, while cyclin D1-dependent kinase activity appears to be solely attributable to Cdk4 or Cdk6 (Matsushime et al., 1994; Meyerson and Harlow, 1994) , cyclin D2 may preferentially activate dierent CDKs in a cell typespeci®c fashion.
The activation of dierent CDKs raises the possibility of diering functions for cyclins D1 and D2. This was investigated in T-47D cells in which the function of cyclin D1 was already well-characterised (Musgrove et al., 1994 . Upon acute cyclin D2 induction following zinc treatment of asynchronous T-47D DMTcyclin D2 cells, an increase in the percentage of cells in S-phase was observed, most likely due to an acceleration through G 1 . While zinc treatment had some eect on cells transfected with vector alone, the increase in the percentage of T-47D DMTcyclin D2 cells in S-phase was consistently greater indicating a speci®c eect of cyclin D2 (Figure 4 ). This has been observed previously in numerous other studies examining ectopic expression of G 1 cyclins including cyclin D2 in a range of dierent cell lines Ohtsubo and Roberts, 1993; Quelle et al., 1993; Musgrove et al., 1994; Resnitzky et al., 1994; Rosenberg et al., 1995) . Ectopic expression of cyclin D2 was followed by increased cyclin E protein abundance and phosphorylation of pRB in vivo responses not observed in vector-transfected cells treated with zinc (Figures 3, 4a and b) . Induction of cyclin E and pRB phosphorylation were also observed following the induction of cyclin D1 in this cell line . There also appears to be an increase in the abundance of total pRB protein following cyclin D2 induction (Figure 4a ). This has been noted before in cyclin transfection experiments including overexpression of cyclin D1 in T-47D cells and may indicate that ppRB is more stable Musgrove et al., 1996) . There appears, therefore, to be a common pattern of molecular events following induction of cyclin D1 or cyclin D2, possibly mediated by the release of E2F upon pRB phosphorylation and consequent induction of cyclin E transcription via E2F sites in the cyclin E promoter (Ohtani et al., 1995; Botz et al., 1996; Geng et al., 1996) .
Under optimal growth conditions the doubling time of T-47D cells expressing cyclin D2 constitutively was not signi®cantly dierent from control cells despite a consistent trend toward slightly faster doubling times in the cyclin D2-expressing cells ( Figure 5 ). MCF-7 breast cancer cells engineered to express cyclin D1 constitutively also showed similar growth rates to parental cells under optimal growth conditions (Zwijsen et al., 1996) , but under reduced serum conditions the percentage of cells in S-phase and the proliferation rate were maintained at higher levels than in control cell lines (Zwijsen et al., 1996) . The latter observation is consistent with results obtained after cyclin D1 overexpression in rodent ®broblasts (Quelle et al., 1993) . In the present experiments, under lowered serum concentrations there was a small but consistent decrease in the doubling times of cyclin D2-overexpressing cells compared to controls which in some cases reached statistical signi®cance ( Figure 5) . However, the doubling time increased in reduced serum conditions, indicating that the cells were not entirely serum-independent, although in some experiments the increase was small. In contrast to the results in serum-containing medium, there was a small but consistent increase in the percentage of cells in S-phase in cyclin D2-expressing cells in serum-free medium. The relatively small magnitude of these eects possibly re¯ects the low level of cyclin D2 achieved relative to the levels in 184 cells ( Figure 7B ). Nevertheless, these results are consistent with the eects of expression of cyclin D1 in MCF-7 breast cancer cells (Zwijsen et al., 1996) .
An initial comparison of the magnitude of the cell cycle changes following induction of cyclin D1 or D2 (Figure 4d and Musgrove et al., 1994) suggested that cyclin D1 may have been more ecient at accelerating cells through G 1 and into S-phase. Indeed, rodent ®broblasts overexpressing cyclin D2 demonstrate a smaller reduction of the G 0 to S-phase transit time compared with cyclin D1-overexpressing cells (Quelle et al., 1993) . Both these studies raise the question of whether cyclin D2 is a less potent stimulator of G 1 progression or whether this re¯ects diering levels of the two cyclins. Quantitation of the amount of cyclin D1 and D2 in the T-47D transfected cells (Figure 7) suggested that equimolar concentrations of the two cyclins would have very similar eects on the fraction of cells accelerated into S-phase. Hence, the seemingly greater cell cycle changes observed after induction of cyclin D1 are most likely a concentration-dependent eect rather than a real indication of functional dierences between the two molecules.
In summary, the data presented in this manuscript indicate that in cells of breast epithelial origin cyclin D1 and cyclin D2 preferentially activated dierent CDKs. Since the cyclin D1-associated CDKs and cyclin D2-associated CDKs phosphorylate dierent substrates in vitro, they appear likely to target dierent substrates in vivo. The observation that they have quantitatively similar eects on cell cycle progression is thus perhaps unexpected and raises the possibility that the pathways activated by Cdk4/ Cdk6 and Cdk2 are redundant. However, inhibition of Cdk2 function inhibits progression into S-phase in normal diploid ®broblasts, in which Cdk4/Cdk6 are presumably active (Tsai et al., 1993) while inhibition of Cdk4 activity via cyclin D1 antibody microinjection inhibits progression into S-phase in the presence of active Cdk2 (Baldin et al., 1993; Quelle et al., 1993) . Furthermore, induction of both cyclins D1 and E shortens G 1 more than induction of either cyclin alone (Resnitsky and Reed, 1995) . While these data argue against redundancy of pathways activated by cyclin D1/Cdk4 and cyclin E/Cdk2, it remains possible that cyclin D2/Cdk2 and cyclin E/Cdk2 have dierent targets. This possibility is supported by evidence from in vitro studies that demonstrate cyclins E, A and B confer distinct substrate speci®cities on CDKs (Peeper et al., 1993; Sarcevic et al., unpublished data) . In addition, it is also possible that some of the actions of cyclin D2 are mediated by interactions with proteins other than CDKs or that the dierent cyclin D/CDK complexes may have roles in addition to promotion of G 1 to S-phase progression. Thus, this study identi®es diculties in assigning a universal function to all Dtype cyclins, and suggests that they may have subtly dierent modes of action to enhance G 1 progression.
Materials and methods

Cell lines and cell culture
The T-47D breast carcinoma cell line from EG and G Mason Research Institute (Worcester, MA) was cloned by limiting dilution, and one clonal cell line, T-47D (7-2), was selected for transfection studies (Musgrove et al., 1994) . T-47D (7-2) retained the characteristics of the parent line by all the tested criteria -i.e., growth rate under standard culture conditions, sensitivity to growth regulation by steroids and steroid antagonists (progestin, ORG 2058, antiestrogen, ICI 164384, and antiprogestin, RU 486) , and abundance of cyclin D1 and c-myc mRNA. Normal breast epithelial cell strain 184 was obtained from Dr Martha Stampfer, University of California, Berkeley, CA, USA.
T-47D cells were maintained in RPMI medium supplemented with 6 mM L-glutamine, 14 mM sodium bicarbonate, 20 mM HEPES, 10 mg/ml human insulin (CSL-Novo, North Rocks, NSW, Australia) and 10% foetal calf serum (FCS). 184 cells were maintained in MEGM medium with 0.4% bovine pituitary extract (BPE) from Clonetics Corp., San Diego, CA, USA. 184 cells were synchronised in these studies by growth factor deprivation. Brie¯y, cells were cultured in MEGM (with BPE) for three days, and then the medium was replaced with MEBM with only 0.05% BPE. The growtharrested cells were rescued three days later by replacing this medium with MEGM containing 0.4% BPE.
The CellTiter 96 non-radioactive cell proliferation assay from Promega was used as per the manufacturers instructions to perform the cell growth assays. Cells were seeded into four replicate wells of a 24-well plate (1.5610 4 cells per well) in 500 ml of RPMI with 5% FCS. After 48 h the cells were washed once in serum-free RPMI before addition of 500 ml of fresh serum-free RPMI or RPMI containing 0.5%, 1.0% or 5.0% FCS. Cells were assayed every other day for 7 days. For each assay replicate wells were stained and solubilised and aliquots were transferred to 96-well plates for measurement of absorbance.
Expression vectors and transfection procedures
The inducible expression vector pDMTcyclin D2 and the constitutive expression vector pRcCMVcyclin D2 were constructed by cloning the human cyclin D2 EcoRI/BglII cDNA fragment from pD2-P39 provided by Drs Yue Xiong and David Beach, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA (Xiong et al., 1992a) , into the SalI site of pDMT (Daly et al., 1991) and the HindIII site of pRcCMV (Invitrogen), respectively. Parallel¯asks of T-47D (7-2) were cotransfected with 40 mg of pDMTcyclin D2 (or pDMT) and 4 mg of pSV2neo, using standard calcium phophate precipitation methods. Similarly cells were transfected with 40 mg pCMVcyclin D2 or pCMV which had the neomycin resistance gene incorporated. Colonies resistant to G418 (600 mg/ml) were pooled after several weeks to produce the following cell lines: T-47D DMTcyclin D2, T-47D DMT, T-47D CMVcyclin D2 and T-47D CMV.
Analysis of cell cycle progression
Analytical DNA¯ow cytometry was used to determine cell cycle phase distribution as described previously (Musgrove et al., 1989) . Brie¯y, cells were stained overnight with the DNA-speci®c dye combination ethidium bromide and mithramycin in the presence of 0.2% Triton to permeabilise the cell membrane. Cell cycle phase distribution was calculated by computer analysis of histograms containing 30 000 events.
Western blot analysis, immunoprecipitation and kinase assays
For immunoprecipitation or Western blot analysis cell monolayers were washed once in ice-cold PBS and then scraped into the following lysis buer: 50 mM HEPES (pH 7.5), 150 mM NaCl, 10% (v/v) glycerol, 1% Triton X-100, 1.5 mM MgCl 2 , 1 mM EGTA, 10 mg/ml aprotinin, 10 mg/ml leupeptin, 1 mM PMSF, 200 mM sodium orthovanadate, 10 mM sodium pyrophosphate, 100 mM NaF. The lysates were incubated on ice for 5 min before clearing cell debris by centrifugation (14 000 g, 5 min) and stored at 7708C until use. Alternatively, cell monolayers were harvested as described below for kinase assays. Similar results were obtained from lysates prepared by either method. For use in kinase assays, cell monolayers were washed once in PBS and scraped into the following lysis buer, on ice: 50 mM HEPES (pH 7.5), 1 mM DTT, 150 mM NaCl, 1 mM EDTA, 2.5 mM EGTA, 0.1% Tween-20, 10% glycerol, 10 mM b-glycerophosphate, 1 mM NaF, 0.1 mM orthovanadate, 10 mg/ml leupeptin, 10 mg/ml aprotinin and 0.1 mM PMSF. Cells were vortexed for 15 s every 10 min for 1 h total before centrifugation to remove cell debris.
For Western analyses equal amounts of protein were separated by SDS ± PAGE and transferred to nitrocellulose ®lters. Non-speci®c binding was blocked in 5% skim milk powder in TBS/Triton (10 mM Tris (pH 7.4), 150 mM NaCl, 0.05% Triton X-100), followed by incubation for 2 h at room temperature in primary antibody, typically at a concentration of 1 mg/ml in TBS/BSA solution (10 mM Tris (pH 7.4), 150 mM NaCl, 5% BSA). Filters were then incubated with the appropriate secondary antibody (1 : 2000 in 5% skim milk powder) for 1 h before enhanced chemiluminescence (ECL) detection (Amersham or Du Pont). Densitometric analysis of autoradiographs was performed using a Molecular Dynamics (Sunnyvale, CA) Personal Densitometer SI and IP LabGel analysis software (Signal Analytics, VA). Antibodies used for blotting were: cyclin D1 (PRAD1), cyclin D2 (C-17), cyclin E (HE12), Cdk2 (M2), Cdk4 (C-22), Cdk6 (C-21), from Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA; pRB (G3-245) from Pharmingen, San Diego, CA, USA; cyclin D1 (DCS6) from Novacastra Laboratories, Newcastle-UponTyne, UK; mouse monoclonal IgG2b isotypic control antibody from Coulter Immunology, Coulter Corporation, Hialeah, FL, USA; sheep anti-mouse and donkey anti-rabbit horseradish peroxidase linked secondary antibodies were from Amersham.
Proteins were immunoprecipitated using either a rabbit polyclonal anti-cyclin D1 serum raised against a human GST-cyclin D1 fusion protein, , rat monoclonal anti-cyclin D2 antibody (34B1-3, Santa Cruz) or a mouse monoclonal anti-cyclin D2 antibody (DCS5, a generous gift from Drs Jiri Bartek and Jiri Lukas, Danish Cancer Society, Copenhagen, Denmark). All cyclin D2 kinase assays were performed using the DCS5 antibody. Lysates were incubated for 3 h at 48C with protein A-sepharose or rat IgG agarose beads that had been pre-conjugated with the appropriate antibody. Beads were then washed four times in ice cold lysis buer and once in 50 mM HEPES (pH 7.5), 1 mM DTT.
Samples used to analyse immunoprecipitated proteins were boiled for 3 min in SDS sample buer (60 mM Tris-HCl (pH 6.8), 10% (v/v) glycerol, 2% SDS, 5% b-mercaptoethanol) before SDS ± PAGE; visualisation of the immunoprecipitated proteins was as described above for Western analysis. Depleted lysate samples were checked for the absence of the immunoprecipitated protein to con®rm that the amount of antibody used in these experiments was sucient to immunoprecipitate all of the protein of interest. Those samples to be used in kinase assays had a further two washes in the HEPES/DTT solution before 20 ml of substrate in HEPES/DTT (4.5 mg GST-pRB (Santa Cruz) or 3 mg histone H1 (Sigma Chemicals)) was added along with 10 ml of 36kinase buer giving a ®nal concentration of: 50 mM HEPES (pH 7.5), 1 mM DTT, 2.5 mM EGTA, 10 mM MgCl 2 , 20 mM ATP, 10 mCi [g-32 P]ATP, 0.1 mM sodium orthovanadate, 1 mM NaF, 10 mM b-glycerophosphate. Samples were mixed gently to resuspend beads and incubated at 308C for 30 min with gentle mixing every 10 min. The reaction was terminated by the addition of 36SDS sample buer (®nal concentration: 60 mM Tris-HCl (pH 6.8), 10% (v/v) glycerol, 2% SDS, 5% b-mercaptoethanol). The samples were then incubated at 908C for 3 min before separation by SDS ± PAGE. Bands were quantitated by densitometry after exposure of the dried gel to X-ray ®lm. If the kinase assay was performed in the presence of inhibitors then the inhibitors were added to immunoprecipitates and incubated for 1 h at 308C prior to the kinase reaction. The bacterially expressed fusion proteins were puri®ed as described elsewhere (Lilischkis et al., 1996) . GST-p16, GST-p21 or GST alone was added in a ®nal volume of 100 ml. The chemical inhibitors roscovitine and olomoucine (a generous gift from Prof Laurent Meijer, CNRS, Station Biologique, Rosco cedex, France) were also added in a ®nal volume of 100 ml in HEPES/DTT giving a ®nal concentration of 50 mM. After the incubation period the inhibitors were aspirated o the beads and the beads were washed once with HEPES/DTT solution before the addition of the substrate and kinase buer.
Production of cyclin GST-D1 and D2 fusion proteins
The cyclin GST-cyclin D1 and GST-cyclin D2 fusion proteins were puri®ed using glutathione-agarose from lysates of Sf-9 insect cells infected with appropriate baculovirus constructs containing the full length ORF of human cyclins D1 and D2, N-terminally linked to GST.
